tbuckley/cabot-search huggingface dataset:
Continuing Anticoagulation Following Venous Thromboembolism—Reply
Authors: David Ost
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Nobel: The Man and His Prizes
Authors: Henrik Schück, Nobelstiftelsen
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Measles-Mumps-Rubella Vaccine in the Italian Armed Forces
Authors: Raffaele D'Amelio
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 12610: Renal Sympathetic Denervation Modulates Ventricular Electrophysiology and Arrhythmogenesis
Authors: Bing Huang, Lilei Yu, Bo He, Zhibing Lu, Songyun Wang, Wenbo He, Kang Yang, Kai Liao, Hong Jiang
Journal: Circulation (2014)

Introduction: Previous studies suggest that renal sympathetic nerves can modulate central sympathetic tone. Recently, a beneficial effect of renal sympathetic denervation (RSD) has been seen in patients with different settings of ventricular electrical storm. However, the effect of RSD on ventricular electrophysiology remains unclear. Methods: Twenty-eight adult mongrel dogs were included in the present study. Eighteen dogs were subjected to RSD which was performed by ablating the adventitial surface of the renal artery. In Group 1 (n=8), programmed stimulation was performed before and after RSD to determinate ventricular effective refractory period (ERP) and action potential duration (APD) restitution properties. In Group 2 (n=10), acute myocardial ischemia (AMI) was induced by ligating the proximal left anterior descending coronary artery after the performance of RSD and the incidence of ventricular arrhythmia (VA) was calculated during 1-hour recording. In another 10 dogs (Group 3), AMI was induced and VA was measured with sham RSD. Results: In Group 1, RSD significantly prolonged ventricular ERP and APD, reduced the maximum slope (Smax) of the restitution curve and suppressed APD alternans at each site (Fig. 1A, C, E). RSD also significantly decreased the spatial dispersions of ERP, APD and Smax (Fig. 1B, D, F). The occurrence of spontaneous VA during 1-h AMI in Group 2 was significantly lower than that in Group 3 (Tab. 1). Conclusions: RSD significantly prolongs ventricular ERP and APD, attenuates APD restitution properties and reduces the incidence of ischemia-induced VA, suggesting that RSD may exert an anti-arrhythmic role for VA.
Tumor necrosis factor (TNF) is a physiologic regulator of hematopoietic progenitor cells: increase of early hematopoietic progenitor cells in TNF receptor p55-deficient mice in vivo and potent inhibition of progenitor cell proliferation by TNF alpha in vitro
Authors: Y Zhang, A Harada, H Bluethmann, JB Wang, S Nakao, N Mukaida, K Matsushima
Journal: Blood (1995)
Abstract 3916: HSP90 mediates tumor-associated matrix metalloproteinase 2 and Cathepsin L protease activities in ovarian carcinoma
Authors: Shane W. O'Brien, Fang Xiao, Marsia A. Maglaty, Joshua S. Trinadad, Lainie P. Martin, David A. Proia, Denise C. Connolly
Journal: Cancer Research (2014)

Abstract Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the United States. At diagnosis, disease has commonly spread beyond the ovary. Ovarian cancer cells dislodge from primary tumor and spread locally throughout the abdominal cavity and lymphatics. Cancer cell shedding and colonization at other sites involves the degradation of extra cellular matrix (ECM) by tumor-associated proteases, such as matrix metalloproteinase (MMPs) and cathepsin proteases. Heat shock protein 90 (HSP90) is an ATP-dependent molecular chaperone that interacts with and stabilizes MMPs in some solid tumors. Whether HSP90 regulates cathepsin activity is currently unknown. To determine the role of HSP90 on tumor-associated MMP and cathepsin protease activities in ovarian carcinoma, HSP90 activity was inhibited using pharmacologic and RNA interference (RNAi) approaches. A small molecule inhibitor, ganetespib, and two HSP90 targeting siRNAs were used to determine the effects of HSP90 inhibition on ovarian carcinoma cell line invasion using transwell and spheroid invasion assays. The effects of ganetespib or HSP90 targeting siRNA treatment on MMP and cathepsin protease activities were assayed by gelatin zymography (MMPs), enzyme assay (cathepsins) and by dynamic imaging using protease cleavable imaging probes. The effects of ganetespib treatment on in vivo orthotopic tumor growth, dissemination and tumor associated protease activities were determined using human ovarian carcinoma xenograft models. In vitro, ganetespib treatment or expression of HSP90-targeted siRNAs inhibited transwell and spheroid invasion, and MMP-2 and cathepsin L protease activities. In vivo, ganetespib treatment resulted in decreased growth of primary tumors and disseminated tumor nodules and decreased tumor-associated MMP and cathepsin activities. Importantly, significant inhibition of MMP and cathepsin activities was detected prior to differences in tumor volume, demonstrating rapid functional response to the drug. These results show that HSP90 regulates ovarian carcinoma-associated proteolytic activities that are essential to tumor progression and dissemination. They also point to the potential utility of HSP90 inhibition as a therapeutic strategy for the treatment of ovarian cancer. Citation Format: Shane W. O'Brien, Fang Xiao, Marsia A. Maglaty, Joshua S. Trinadad, Lainie P. Martin, David A. Proia, Denise C. Connolly. HSP90 mediates tumor-associated matrix metalloproteinase 2 and Cathepsin L protease activities in ovarian carcinoma. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3916. doi:10.1158/1538-7445.AM2014-3916
Effect of naltrexone on alcohol "high" in alcoholics
Authors: J R Volpicelli, N T Watson, A C King, C E Sherman, C P O'Brien
Journal: American Journal of Psychiatry (1995)

Subjective effects of alcohol in alcoholics treated with naltrexone or placebo were compared.In a previously reported double-blind clinical trial of 50 mg/day of naltrexone or placebo for treatment of alcoholism, 36 of 70 detoxified male veterans deviated from abstinence. Of these 36, 29 subsequently reported on the subjective effects of drinking during the trial.A larger proportion of naltrexone-treated subjects (seven of 12) than placebo-treated subjects (two of 17) reported that the "high" produced by alcohol during the study was significantly less than usual. The naltrexone-treated subjects also drank less alcohol than the placebo-treated subjects during the first drinking episode. There was no difference between groups in reported intoxication, craving, memory, or loss of temper.The lower alcohol consumption by the naltrexone-treated subjects may have resulted from naltrexone's blockage of the pleasure produced by alcohol.
Abstract 4181: Accurate and fast detection and comparison of larger clinically relevant insertions and deletions
Authors: Anne-Mette K. Hein, Patrick Dekker, Anika Joecker, Cecilie Boysen, Naomi Thomson, Bodil Oester, Anne Arens, Bjarne Knudsen, Thomas Knudsen, Roald Forsberg
Journal: Cancer Research (2014)

Abstract Larger somatic insertions and deletions in tumor samples are often of significant clinical impact. Many of them are cancer driver mutations and play an important role in drug treatment1. Detecting the accurate breakpoints of larger insertions and deletions is often problematic and inaccurate. Furthermore, due to ambiguous positioning of them in the human genome, they are hard to compare with known deletions and insertions in publicly available databases. Here we present a complete analysis workflow to accurate identify, filter and annotate larger insertions and deletions with information from publicly available databases such as COSMIC. We apply our pipeline on publicly available tumor/normal matched pair data from a patient with Massive Acinic Cell Carcinoma (A. Nichols et al. (2013) Case Reports in Oncological Medicine, Article ID 270362), which has not been investigated for larger insertions and deletions before. We show that we can identify insertions and deletions, which should be reported as part of the list of somatic variants, the authors have presented. Moreover, we will point out potential challenges and how to solve them while comparing own results to data in databases. Citation Format: Anne-Mette K. Hein, Patrick Dekker, Anika Joecker, Cecilie Boysen, Naomi Thomson, Bodil Oester, Anne Arens, Bjarne Knudsen, Thomas Knudsen, Roald Forsberg. Accurate and fast detection and comparison of larger clinically relevant insertions and deletions. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4181. doi:10.1158/1538-7445.AM2014-4181
Drug Approved for Rare Lung Disease
Authors: Rebecca Voelker
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine–Refractory Differentiated Thyroid Cancer
Authors: Abhilasha Nair, Steven J. Lemery, Jun Yang, Anshu Marathe, Liang Zhao, Hong Zhao, Xiaoping Jiang, Kun He, Gaetan Ladouceur, Amit K. Mitra, Liang Zhou, Emily Fox, Stephanie Aungst, Whitney Helms, Patricia Keegan, Richard Pazdur
Journal: Clinical Cancer Research (2015)

The FDA approved lenvatinib (Lenvima, Eisai Inc.) for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory (RAI-refractory) differentiated thyroid cancer (DTC). In an international, multicenter, double-blinded, placebo-controlled trial (E7080-G000-303), 392 patients with locally recurrent or metastatic RAI-refractory DTC and radiographic evidence of disease progression within 12 months prior to randomization were randomly allocated (2:1) to receive either lenvatinib 24 mg orally per day (n = 261) or matching placebo (n = 131) with the option for patients on the placebo arm to receive lenvatinib following independent radiologic confirmation of disease progression. A statistically significant prolongation of progression-free survival (PFS) as determined by independent radiology review was demonstrated [HR, 0.21; 95% confidence interval (CI), 0.16-0.28; P < 0.001, stratified log-rank test], with an estimated median PFS of 18.3 months (95% CI, 15.1, NR) in the lenvatinib arm and 3.6 months (95% CI, 2.2-3.7) in the placebo arm. The most common adverse reactions, in order of decreasing frequency, observed in the lenvatinib-treated patients were hypertension, fatigue, diarrhea, arthralgia/myalgia, decreased appetite, decreased weight, nausea, stomatitis, headache, vomiting, proteinuria, palmar-plantar erythrodysesthesia syndrome, abdominal pain, and dysphonia. Adverse reactions led to dose reductions in 68% of patients receiving lenvatinib at the 24 mg dose and 18% of patients discontinued lenvatinib for adverse reactions leading to residual uncertainty regarding the optimal dose of lenvatinib.
HYPERPARATHYROIDISM—SIMULATING PAGET'S DISEASE
Authors: Sidney P. Zimmerman
Journal: Annals of Internal Medicine (1949)

Case Reports1 March 1949HYPERPARATHYROIDISM—SIMULATING PAGET'S DISEASESIDNEY P. ZIMMERMANSIDNEY P. ZIMMERMANSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-30-3-675 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe consensus among investigators interested in bone disease is that generalized osteitis fibrosa cystica (Von Recklinghausen's disease) and osteitis deformans (Paget's disease), represent two definite, independent, clinical entities.1, 2, 3, 4The former, due to hyperparathyroidism, has a clinical, roentgenologic, and biochemical picture which is distinct from the latter, whose cause is unknown and which manifests its own clinical and laboratory characteristics. This view applies to practically all of the cases presenting the respective picture of these two disorders. There are, however, several reports of cases in the literature which do not quite fit into either category but which appear...Bibliography1. ALBRIGHTAUBBAUER FJCW: Hyperparathyroidism, Jr. Am. Med. Assoc., 1934, cii, 1276. CrossrefGoogle Scholar2. GUTMANPARSONS ABWB: Hyperparathyroidism, Ann. Int. Med., 1938, xii, 13. Google Scholar3. COUCHROBERTSON JHHF: Occurrence of postoperative acidosis and pagetoid bone changes in hyperparathyroidism, Surg., Gynec. and Obst., 1941, lxxiii, 165. Google Scholar4. SNAPPER I: Medical clinics on bone diseases, 1943, Interscience Publishers, New York City. Google Scholar5. SCHMORL G: Demonstration, Verhandl d. Deutsch. path. Ges., 1919, 352. ASK-UPMARK, E.: Further observations on osteitis fibrosa generalisata, Acta. chir. Scandinav., 1931, lxviii, 551. Google Scholar6. BERBLINGER CW: Beitr. z. path. Anat. u. z. allg. Path., 1935, xciv, 558. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication April 26, 1947.From the Third (New York University) Division, Dr. J. M. Steele, Director, Goldwater Memorial Hospital, and the Department of Medicine, New York University College of Medicine.†Formerly Resident in Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCoexistence of Primary Hyperparathyroidism and Paget DiseaseWhat Is the Relationship Between Paget's Disease of Bone and Hyperparathyroidism?Occupational and environmental exposure to lead and Paget's disease of boneHYPERPARATHYROIDISM ASSOCIATED WITH PAGET'S DISEASE*NORMAN N. KOHN, M.D., RALPH M. MYERSON, M.D., F.A.C.P. 1 March 1949Volume 30, Issue 3Page: 675-681KeywordsBoneClinical laboratoriesHospital medicineHyperparathyroidismNeurofibromatosis type 1Research laboratories ePublished: 1 December 2008 Issue Published: 1 March 1949 PDF downloadLoading ...
Major allergens of date palm (<i>Phoenix dactylifera</i> L.) pollen
Authors: A. A. A. Kwaasi, R. S. Parhar, P. Tipirneni, H. Harfi, S. T. Al‐Sedairy
Journal: Allergy (1993)

The IgE-binding components of date palm (Phoenix dactylifera L.) pollen were determined by ELISA and Western blotting in atopic patients in order to identify its major allergens. From a pool of previously identified allergenic fractions and sera from 15 skin-test-positive, atopic subjects, four components of 12, 14.4, 57, and 65-67 kDa were found to bind IgE in 80-93% of sera. Two other components of molecular masses 28-30 and 37-40 kDa also bound 60-80% of atopic sera. The immunologic specificity of date-pollen allergen that induced antibody response in sera of atopic patients was confirmed with ELISA. Furthermore, most of the reactivity in pooled positive atopic serum and antiserum raised in rabbits was eliminated after the sera were absorbed with the allergen. IgG immunoblot analyses showed varying degrees of cross-reactivity with common local allergens, notably Bermuda grass, but were generally of low intensity. These results indicate that date pollen has six major allergens with the 12, 14.4, 57, and 65-67 kDa bands binding 80-93%, and the 28-30 and 37-40 kDa bands 60-80% of atopic sera. We propose that these major allergens be assigned the notations "Pho d I" to "Pho d VI" in the order listed.
Treatment of Sarin Exposure—Reply
Authors: Ernest C. Lee
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 20492: Mlf1 Regulates Myocyte Proliferation in Postnatal Hearts
Authors: Shalini Muralidhar, Feng Xiao, Suwannee Thet, Hesham Sadek
Journal: Circulation (2014)

Lower vertebrates, such as newt and zebrafish, retain a robust cardiac regenerative capacity following injury. Although adult mammals lack this cardiac regenerative potential, there is ample interest in understanding how heart regeneration occurs, and to reawaken this process in adult humans. Recently, we showed that mice are capable of regenerating their hearts shortly after birth following injury. This regenerative response is associated with robust proliferation of cardiomyocytes without significant hypertrophy or fibrosis. However, this regenerative capacity is lost by 7 days postnatally, coinciding with cell cycle arrest. In an effort to determine the mechanism of cardiomyocytes cell cycle arrest after the first week of life, we performed a gene array after cardiac injury at multiple post-natal time points. This enabled us to identify a number of transcription factors that are differentially expressed during this postnatal window. We recently reported that one of these transcription factors Meis1 regulates postnatal cell cycle arrest of cardiomyocytes. Furthermore, Myeloid leukemia factor 1 (Mlf1), a bhlh transcription factor that has not been previously studied in the heart has similar dysregulated pattern following injury. Our preliminary data with in-vitro knockdown of Mlf1 in cardiomyocyte resulted in 2-fold increase in cardiomyocyte proliferation. Furthermore, immunohistochemistry results indicated that the endogenous expression and nuclear localization of Mlf1 in the post-natal cardiomyocytes coincides with cell cycle arrest. To explore this pattern, we generated a cardiomyocyte-specific Mlf1 knockout mouse, and showed that loss of Mlf1 results in robust cardiomyocyte proliferation in postnatal hearts (P14). Additionally, we confirmed previous reports that Mlf1 regulates p53 and induces cell cycle arrest by induction of CDK inhibitors like p21 and p57 in these Mlf1 KO mice. This suggests a role of Mlf1 in promoting reactivation of injured myocardium through induction of cardiomyocyte proliferation. These findings will further provide evidences of molecular mechanisms involved in the dormant regenerative capacity in adult mammals that can be a potential target of therapeutic approaches.
Clinical and Angiographic Outcome After Implantation of Drug-Eluting Stents in Bifurcation Lesions With the Crush Stent Technique
Authors: Lei Ge, Flavio Airoldi, Ioannis Iakovou, John Cosgrave, Iassen Michev, Giuseppe M. Sangiorgi, Matteo Montorfano, Alaide Chieffo, Mauro Carlino, Nicola Corvaja, Antonio Colombo
Journal: Journal of the American College of Cardiology (2005)